Our Mission

Numedicus Limited was established in 2008 to provide collaborative services to companies seeking expert advice in
the area novel uses for existing drugs, or ‘drug repurposing’.

Our Services

post
post

Types of collaborator

Numedicus uses therapeutic switching to identify secondary uses for existing drugs in practically all areas.

Read More
post

Types of switch

Therapeutic Switch, or drug repurposing projects, come in various different flavours

Read More
post

Methods and output

There are various different methods of identifying drug repurposing projects

Read More
post

Track Record

Numedicus has identified a number of clinical-stage drug repurposing projects, supported by method-of-use patents

Read More

New book!

Off-Label Prescribing: Justifying Unapproved Medicine

Today’s medicines are regulated for their efficacy and safety and, once approved, they can be marketed for certain uses as justified by the data. Regulatory bodies in developed countries are constituted by legal statute and operate as parts of government, ostensibly in the interests of the people as patients.

But once approved, medicines can be used for any purpose the prescriber thinks fit and appropriate for the patient. One in five prescriptions is therefore written outside regulatory purview.

Off–label Prescribing looks into the corners of our medicated lives, where drug regulation runs up against medical practice, and concerns the use of a drug that has been approved for a different indication or on a different set of patients from the ones it is approved for, or at a different dose. Usually the patient is unaware of what is going on, having not been informed by their doctor of this aspect of his or her prescribing choice.

Reviews

1 Star2 Stars3 Stars4 Stars5 Stars
Loading...

3 months ago

A fascinating read lot more balanced and intellectually satisfying than the much higher profile Bad Pharma essential reading’, Medicines Information Director, NHS

1 Star2 Stars3 Stars4 Stars5 Stars
Loading...

3 months ago

‘Impressive fact-finding!’ department Head, AstraZeneca